Clinic YouTube Channel

Performed performances (videos)

Percutaneous coronary intervention of the left coronary artery
Left ventricular electrode implantation
Catheter closure of multiple atrial septal defect
Catheter closure of atrial septal defect
Catheter ablation of AV nodal reentry tachycardia (AVNRT)
Non-selective catheter ablation of the AV junction
Catheterization of pulmonary veins with cryobalon
ICD implantation step by step
Carotid stenting
Catheter ablation of ventricular ectopy
Biventricular pacemaker implantation step by step
Catheter implantation of aortic bioprosthesis in a high-risk patient with LV systolic dysfunction
Alcohol septal ablation
Catheter treatment of femoral artery occlusion
Catheter implantation of aortic bioprosthesis in an 86-year-old patient
Electrical cardioversion
Covid - 19 Pneumonia - Care of hospitalized patients

Management and staff

Head:

prof. MD Oštádal Petr, Ph.D., FESC
phone: 2 2443 4901
Email: petr.ostadal@fnmotol.cz

Primary:                  

MD Vejvoda Jiří, MHA
tel .: 2 2443 4952
Email: jiri.vejvoda@fnmotol.cz 

Head nurse:   

M.Sc. Kovalčíková Jana
tel .: 2 2443 4905
Email: jana.kovalcikova@fnmotol.cz 

Chief doctors

MD Alan David - Coronary unit
tel .: 2 2443 4952
Email: david.alan@fnmotol.cz 

Doc. MD Honěk Jakub, Ph.D. - Arrhythmology
phone: 22 44 34 964
Email: jakub.honek@fnmotol.cz

MD Tesař David, CSc. - Catheterization rooms
phone: 2 2443 4961
Email: david.tesar@fnmotol.cz

Doc. MD Teplá Riedlbauchová Lucie, PhD. - Ambulance
tel .: 2 2443 4964, 4914
Email: lucie.riedlbauchova@fnmotol.cz

MD Horváth Martin, Ph.D. - Echocardiography laboratory
phone: 224 434 973
Email: martin.horvath2@fnmotol.cz

MD Adlová Radka, M.D. Ingrid Homolova -  1st bed station
phone: 2 2443 4953
Email: radka.adlova@fnmotol.cz, ingrid.homolova@fnmotol.cz

MD Jiří Bonaventura, Ph.D., MUDr. Tomis Jan - 2st bed station
phone: 2 2443 4955
Email: jiri.bonaventura@fnmotol.cz, jan.tomis@fnmotol.cz

MD Petra Zimolová -  Angiology
phone: 2 2443 4969
Email: petra.zimolova@fnmotol.cz

Doctors

MD Adlová Radka
MD Alan David
MD Bonaventura Jiří, Ph.D.
MD Kristýna Borovanová
MUDr. Butta Tadeáš
MD Čadová Pavla
MD Davydiuk Maxim
MD Davydiuk Natalia
MUDr. Durdil Václav
MD Durdilová Denisa
MD Frank Antonová Petra
MD Jiří Fiedler
MD Klára Fulínová
MD Gašpárková Veronika
doc. MD Hájek Petr, Ph.D.
MD Hladká Katarina
MD Hnat Tomas
MD Hnátek Tomáš, Ph.D.
MD Hnátová Hana
MD Ingrid Homolová
doc. MD Honěk Jakub, Ph.D.
MD Horváth Martin, Ph.D.
MD Chabová Barbora
MD Jana Choi-Širůčková
MD Jenšovský Michael
MD Kala Petr, Ph.D.
MD Kmoníček Petr
MD Hana Línková, Ph.D.
Lytovchenko Kateryna - doctor
MD Šimon Macháček
MD Matula Jan
MD Oravec Milan
prof. MD Petr Oštádal, Ph.D.
MD Pham Thi My Hanh
MD Poláková Eva
doc. MD Rubáčková Popelová Jana, CSc.
MD Prokopcová Adéla
MD Veronika Puchner
doc. MD Warm Lucie Riedlbauch, Ph.D.
MD Řeháček Jan
MD Barbora Řiháková
MD Cyril Štěchovský, Ph.D.
MD Přemysl Šváb
MD Zuzana Tekulová
MUDr. Tesař David, CSc.
MD Tomis Jan
MD Topalo Robert
MD Varon Izová Luna Kateřina
MD Vejvoda Jiří, MHA
MD Vondráková Dagmar, Ph.D.
MUDr. Zimolová Petra

Chief physician of the outpatient clinic:

Doc. MD Lucie Teplá Riedlbauchová, Ph.D.
tel .: 2 2443 4914, 4941
Email: lucie.riedlbauchova@fnmotol.cz

Office hours: 7:00 a.m. - 15:00 p.m

General ambulance

At the general cardiology outpatient clinic, specialist outpatient examinations are performed on patients with suspected acute manifestations of heart disease. The operation of the ambulance is non-stop, there is no need to order an examination.

Cardiology clinic 

The cardiology clinic is used to monitor patients with cardiovascular diseases that require regular check-ups.

Arrhythmology clinic

The arrhythmology outpatient clinic is used for examination and subsequent monitoring of patients with heart rhythm disorders. It also includes a pacemaker outpatient clinic, in which patients are regularly monitored after implantation of a permanent pacemaker. The arrhythmology group performs over 4500 inspections a year.

Heart failure clinic

The ambulance is specialized in the diagnosis and treatment of heart failure, differential diagnosis of the causes of heart failure, including endomyocardial biopsy (in cooperation with invasive cardiologists), setting optimal medical treatment, indications and ensuring resynchronization treatment of heart failure (implantation of a biventricular pacemaker) in cooperation with the arrhythmology group.

Hypertrophic cardiomyopathy clinic

The hypertrophic cardiomyopathy clinic specializes in the diagnosis, monitoring and treatment of patients with this disease, including alcohol ablation of the interventricular septum. The group of patients with this rare disease is the largest in the Czech Republic.

Outpatient congenital heart disease clinic

The outpatient clinic focused on the diagnosis, treatment and monitoring of adult patients with congenital heart defects and after operations for congenital heart defects, works closely with the Children's Cardiac Center of the National Hospital.

Ambulance of valve defects

The valve defect clinic is focused on comprehensive diagnostics, dispensary treatment and treatment of patients with valve defects and aortic disease, indications and surgical treatment of valve defects at the Cardiac Surgery Department of the Cardiovascular Center of the National Hospital.

Angiology clinic

The ambulance searches for, dispensaries, examines and treats patients with dg.

• extracranial artery disease
• pelvic and peripheral artery diseases (acute and chronic)
• diseases of the abdominal aorta (arterial edema, stenosis)
• diseases of the pelvic and peripheral veins (acute and chronic)

Ambulance

chief outpatient physician:    Doc. MUDr. Teplá Riedlbauchová Lucie, Ph.D. 
tel .: 2 2443 4914, 4941
Email: lucie.riedlbauchova@fnmotol.cz

Station nurse: Pekařová Marie 

Acute ambulance - ambulance No. 2

Cardiology consulting room, Echo - ambulance no. 9

Cardiology consulting room, Echo - ambulance no. 6

Cardiology consulting room, Echo - ambulance no. 7

Cardiology consulting room, Holter EKG, Spirometry - ambulance no. 8

Cardiology consulting room - ambulance no. 5

Angiology Clinic - Ambulance No. 4

Angiology Clinic - Ambulance No. 1

Arrhythmological outpatient clinic - outpatient clinic No. 10 

Cardiostimulation consulting room - ambulance no. 11 

The bed capacity of the clinic is 60 beds at two standard stations and 12 acute coronary unit beds.
Rooms in standard departments are triple, each room has a bathroom, including toilet and shower. The equipment of the rooms, examination rooms and common areas is of a high standard and meets the modern demands of patient care. The bed stations also include single or double superior rooms, which are also equipped with their own telephone and TV. The beds in the single rooms are automatically adjustable. Part of the beds is equipped with telemetric ECG monitoring.
Acute beds in the coronary unit are fully equipped for quality intensive care, resuscitation, artificial lung ventilation, hemodynamic monitoring and temporary endovascular pacing.

Care in each standard ward is provided by a team of 4-6 physicians and 10 nurses, and a team of 2-3 physicians and 22 nurses works on the coronary unit.

Come and support our cardiology team

The team of senior staff of the NZO Cardiology Clinic

We offer you

Interesting work at one of the best workplaces in the Czech Republic:

1st bed station - standard ward - 30 beds
2st bed station - standard ward - 30 beds

Coronary unit - ICU - 12 beds

Outpatient tract - 9 professional counseling centers with a reception

Catheterization and arrhythmology halls

A young and pleasant team

Benefits in the form of bonuses from FN Motol www.fnmotol.cz

Vacancies - Doctors

Vacancies - NZO

Sanitary for the Cardiology Clinic

General nurse / practical nurse / paramedic at the Cardiology Department.

We are a modern workplace providing comprehensive care for patients with heart and vascular diseases. We are one of the largest centers in the Czech Republic in terms of the scope of care provided and the number of procedures, and we have the status of a comprehensive cardiovascular center.
At our workplace, the latest examination and treatment procedures are being put into practice. In the field of interventional cardiology, these are mainly catheter implantation of aortic valve bioprosthesis, coronary artery intervention using drug stents, carotid artery intervention, catheter occlusion of the atrial septum, alcohol septal ablation in hypertrophic obstructive cardiomyopathy, catheter closure of the left atrial ear or coronary artery optical coherence tomography. In the field of treatment of heart rhythm disorders, it is also a complete spectrum of catheterization and implantation procedures, especially catheter isolation of pulmonary veins, catheterization treatment of complex supraventricular and ventricular arrhythmias, cardiac resynchronization therapy and implantation of implantable cardioverter defibrillator. New techniques such as three-dimensional echocardiographic examination or imaging of the heart using nuclear magnetic resonance and a multidetector computed tomograph are being introduced in the non-invasive diagnosis of heart diseases. 

The latest examination and treatment procedures are being put into practice at our workplace - recently they are mainly coronary artery interventions using drug stents, carotid artery interventions, catheter closures of the atrial septum, alcohol septal ablation in hypertrophic obstructive cardiomyopathy, virtual histology coronary arteries, cardiac resynchronization therapy using an implanted pacemaker, or the introduction of new techniques in the non-invasive diagnosis of heart disease, such as three-dimensional echocardiography or nuclear magnetic resonance imaging and multidetector computed tomography. 

Our workplace is equipped with the latest technologies used in the diagnosis and treatment of heart disease. Above-standard equipment includes, for example, intravascular ultrasound with the possibility of virtual histology and modern echocardiographic devices enabling a whole range of imaging, including three-dimensional imaging of the heart. In cooperation with the Department of Imaging Methods, we are intensively using the most modern computed tomography device in the Czech Republic, which enables very accurate imaging of the heart and adjacent tissues. 

Examinations and procedures

• Bicycle ergometry
• Echocardiography
• 24 hour ECG monitoring
• Outpatient 24-hour blood pressure monitoring
• Pacemaker implantation
• Passive verticalization test on an inclined plane
• Electrophysiological examination
• Cardiac catheterization

The aim of this examination is the diagnosis of coronary artery disease (CHD) based on ECG changes and typical clinical difficulties arising during exercise. Decreased heart muscle performance leads to abnormal heart rate, heart rhythm disorders, ECG signs of insufficient blood flow to the heart muscle.
The examination evaluates the cardiac response with increased demands on oxygen supply.
It is performed either on a bicycle ergometer (or a load on a treadmill, winch, ..).
During the examination, the load gradually increases, which leads to an increase in heart rate.
The ECG, heart rate and blood pressure are monitored continuously during the examination.
The examination is performed as an auxiliary method in the diagnosis of the cause of chest pain, the cause of which may be a restriction of blood flow in the arteries supplying the heart muscle (so-called myocardial ischemia). This may be due to the presence of significant coronary artery stenosis.

Indications for examination:

• Diagnosis of so-called coronary heart disease (CHD) ¨
• Determining the effectiveness of prescription drugs.
• Diagnosis of irregular heartbeats that may occur during exercise.
• Rehabilitation design for patients after myocardial infarction, for patients undergoing chronic heart failure.

Examination procedure

The stress test is performed in a cardiology examination room.
A doctor is present during the examination.
Before starting the examination, the electrodes are attached to the patient's chest and secured.
A resting electrocardiogram is recorded before the examination.
The examination is started by the patient starting to walk slowly on the examination wheel.
After a few minutes, at regular intervals, the load (the resistance to which the patient treads) begins to increase.
At the same time, as the intensity of the load increases, the heart's oxygen requirements begin to increase.
During the examination, blood pressure is measured at regular intervals (the measuring cuff is placed on the arm), and the ECG curve is monitored continuously.
The patient is encouraged to report any symptoms that may occur during the examination (chest pain, dyspnoea, dizziness, feeling faint).
In case of chest pain, shortness of breath, general exhaustion vyšetření the examination is terminated.
The duration of the examination is usually approximately 15 minutes.
At the end of the test, the doctor will evaluate the course of the examination.

Preparation for the examination

It is recommended not to eat or drink in large quantities or smoke for at least 3 hours before the examination.
Do not perform unusual physical exertion for at least 12 hours before the examination.
Wear comfortable sports shoes.
Discontinue nitrates (Cardiket, Isomer, Iso-Mack, Mycor, Nitro-Mack, Mono Mack, Olicard, Sorbimon, Corvaton, Molsihexal…) 24 hours before examination in patients with mild angina pectoris (diagnostic tests) - these drugs suppress the clinical response on the load, may increase the load tolerance.
Discontinue beta-blockers (eg Vasocardin, Betaloc, Egiloc, Tenormin, Concor, Lokren, Sectral 2-3) XNUMX-XNUMX days before the examination (in case of a diagnostic test), with event. by substituting a drug from another group of antihypertensive medication for good blood pressure compensation before examination.

Results

The stress test makes it possible to evaluate the function of the heart in response to physical activity, when there is an increasing demand for oxygen.
The exercise test can lead to the detection of ECG signs of insufficient blood supply to the heart muscle, abnormalities of the heart rhythm occurring only during physical exertion.
If the test is positive - the occurrence of typical chest pain (astringent chest pain caused by exercise and resolving after exercise interruption or nitroglycerin administration) or specific ECG changes - there is a high probability of coronary heart disease and your doctor may recommend another exercise. examination, event. angiographic examination of the heart. The presence of risk factors, age, gender, nature of pain, family and personal history are taken into account when deciding on further diagnostic and treatment procedures.

Risks and complications of examination

The most serious cardiac complications include acute myocardial infarction (0,05%) or malignant arrhythmias, which are immediately recognized and treated appropriately.
The risk is higher in patients with established ischemic heart disease, especially in the early phase of myocardial infarction.
The risk of sudden death is about 0,01%
Other non-cardiac complications - muscle or joint disorders, neurological symptoms, dizziness, weakness, persistent fatigue, etc.

Echocardiographic examination is one of the key examinations in cardiology. It provides valuable information on heart muscle contractile disorders, heart valve dysfunction and the presence of other heart defects. The principle of the examination is the imaging of the heart using ultrasound waves. The examination is usually performed "across the chest" (transthoracically) and is not burdensome for the patient. An ultrasound probe applied to the chest examines the heart through a thin layer of conductive gel (which allows for better imaging) and evaluates its function, size, valve condition, etc.
Approximately 10% of patients are not "chest-proof" of sufficient quality. Chest inflammation or the presence of blood clots in the heart cavities cannot be ruled out with chest examinations either. In these cases, esophageal echocardiography (transesophageal) should be performed.

Transesophageal echocardiography

The method uses the close vicinity of the esophagus and the heart. During the examination, a flexible little-thickness probe is inserted into the esophagus, at the end of which there is an ultrasonic transducer.
Before the examination, inform the medical staff about allergies, diseases of the oral cavity, pharynx or esophagus. Six hours of fasting is necessary before the examination. We also do not allow the use of morning medications, which are postponed until one hour after the examination. Before the examination, remove the denture or removable dentures, if you have them. The nurse will insert a cannula into your peripheral vein. If the examination is not well tolerated or if you have difficulty inserting the probe into your esophagus, we will give you a sedative in the cannula. If necessary, the contrast agent will be given to you intravenously to improve the diagnostic yield of the examination. .The examination is unpleasant, but painless and the patients usually tolerate it well.
The probe is inserted into the neck sitting or lying on the left side. You will be asked to breathe regularly through your nose and try to swallow the probe. After the probe penetrates the esophagus, you will be relieved, but a slight feeling of vomiting and occasional vomiting may persist. The doctor then performs the actual examination for the necessary length of time with constant ECG monitoring.
Due to local anesthesia, you must not eat or drink for another hour after the examination. You would be at risk of inhalation. If you have been given a sedative injection, you must not drive or engage in any activity that requires extra attention for 24 hours after the examination.

Exercise echocardiography

Early diagnosis of coronary heart disease (CHD) before its severe manifestations, which include sudden death, myocardial infarction, and heart failure, is a major goal of diagnostic stress echocardiography. Resting examinations often do not provide sufficient information, and therefore the diagnosis of coronary heart disease is based on signs of myocardial ischemia (circulatory disorders) during exercise. The so-called Exercise echocardiography combines echocardiography (ultrasound examination of the heart) with various forms of exercise: the most commonly used pharmacological load (dobutamine is given intravenously in continuous infusion in graded doses) or dynamic load on an ergometer. In patients who have a significantly narrowed coronary artery, echocardiography can detect cardiac wall movement disorders.

Contrasting echocardiography

Contrast echocardiography is an ultrasound diagnostic method that uses echo-contrast agents to visualize cardiac structures. The method is mainly used to diagnose various congenital heart defects, such as a atrial septal defect. State-of-the-art ultrasound techniques also allow direct imaging of the perfusion (or perfusion) of the heart muscle (see figure: arrow shows myocardial perfusion defect in the apex).

The principle of this examination is a continuous electrocardiogram (ECG) recording for 24 (less often 48) hours. Your doctor will recommend this test if you have a suspected heart rhythm disorder.
The examination consists of gluing the electrodes to the skin of the chest and connecting these electrodes to the monitoring unit itself, which weighs about 200 g, which is hung around the neck. The device is put on in the morning (usually at 8:00 am) and removed the next day. In the meantime, the electrocardiogram is recorded and stored in the device's memory, during this time you can perform normal daily activities without restrictions, unless your doctor tells you otherwise, but care must be taken to ensure that the electrodes do not come off the chest (eg sweat). The examination is performed on an outpatient basis and therefore hospitalization is not necessary. At the same time, you will be asked to record your physical exertion and event. difficulties on the attached sheet of paper together with the current time so that the doctor can compare this information with the electrocardiographic record.

The aim of this examination is continuous 24-hour monitoring of blood pressure (blood pressure) values. The examination is usually started in the morning by using a digital tonometer with a cuff, which is then inflated at regular intervals - during the day after 1 hour, during the night after 2 hours and automatically measures blood pressure. The examination is completely without complications, the only limitation is a certain discomfort due to the deployed device. Based on the information obtained, we can effectively adjust the therapy in patients treated with high blood pressure after evaluation, or we can diagnose new patients, not caught during the sudden blood pressure measurement at rest in the doctor's office.

This is an examination that the doctor recommends when investigating the cause of short-term unconsciousness. During the examination, the examinee is placed on a folding bed, which is gradually tilted during the examination together with the examinee to a vertical position. The blood pressure and electrocardiogram of the examinee are monitored during the examination. During the examination, there may be a significant drop in blood pressure or heart rate, which may result in a feeling of fainting or a brief unconsciousness - the test is then evaluated as positive and the patient is recommended targeted treatment. The total examination time is about 60 minutes, the examination is minimally burdensome and has practically no complications, the examined person is under the control of medical staff at all times.

Electrophysiological examination is an invasive catheterization method that involves recording intracardiac electrical signals and / or programmed electrical pacing.

Description

The aim of this examination is to clarify the nature of the heart rhythm disorder or to find the area of ​​the heart muscle (the so-called arrhythmogenic lesion) in the right atrium or right ventricle, which may be the source of your problems. Based on the results of the examination, we will decide on the suitability of further therapy - either drug therapy, the introduction of a permanent pacemaker or radiofrequency catheter ablation.
The examination is performed in a pacing room. You will not eat or drink for 6 hours before the examination. smoke. If you have a denture, you will remove it. You will be conscious during the examination. You will be constantly monitored by Ekg. The examination is performed under local anesthesia under strictly sterile conditions. The examination is painless, you only feel a slight pressure during the injection.
Under X-ray control, catheters are inserted into the right half of the heart via large veins (femoral puncture from the groin area or subclavian area from the area above the collarbone). There are usually two, event. four electrodes that are plastic and terminated in a metal contact. They are placed in various places in the heart and with their help the electrical activity in the heart is directly sensed and it is possible to stimulate the heart (stimulate mechanical contraction by an external stimulator). By stimulating the heart, we try to cause an atrial or ventricular arrhythmia (arrhythmia), which can be the cause of your current problems. From the heart's response to stimulation, it is possible to determine the type and severity of the heart rhythm disorder. If the arrhythmia is triggered, it can be canceled either again by stimulation (so-called extrastimuli) or by medication (medication) or by electric shock (defibrillation). If you have any problems (pain, shortness of breath, palpitations) during the procedure, inform the examining doctor immediately.

Risk

The risk of the procedure is small, in most cases the examination is without complications. The diagnostic benefits and benefits for subsequent therapy certainly outweigh them. It can happen vascular injury, to form blood clots (thrombi) and occlude the blood vessels with a clot or to form a vascular bulge. It can happen bleeding from the injection site with hematoma formation. A subclavian vein puncture may occur penetration of air or blood into the pleural cavity with event. the need to aspirate air or fluid through a stronger catheter (in collaboration with a surgeon). Local may occur at the injection site infection skin and subcutaneous tissue, the infection can rarely go through the bloodstream to the heart. In this case, antibiotics are indicated. It is a rare complication injuries to cardiac structures electrode, which may require cardiac surgery. For longer exposure to X-rays redness, hair loss, transient pigmentation may appear on the irradiated area of ​​the skin in 2-4 weeks. These skin changes gradually subside, in the unfavorable case, an ulcer on the skin may develop.

Selective coronary angiography (SKG), percutaneous coronary intervention (PCI).

Examination procedure

Catheterization examination is performed in the catheterization room under the X-ray machine. The operation takes place under local anesthesia after the injection, most often into the femoral artery in the right groin (another option is the femoral artery in the left groin or the arteries of the upper limbs). Thin plastic catheters are inserted into the heart vessels. An X-ray contrast agent is then injected into these arteries (when administered with the possibility of a feeling of heat, which quickly subsides), which shows the entire course of the coronary arteries (coronary angiography) and allows to determine the presence, number, exact location and significance of coronary artery stenosis or event. the presence of an artery occlusion. It is also possible to visualize the left ventricular cavity (levography) or the main artery of the body - the aorta (aortography), which is important to assess left ventricular contraction and valve function. The examination is painless, the vessels are not sensitive and manipulation of the catheter is not perceived in them. During the whole exercise you will be aware while lying on your back, you can talk to the doctor and watch the progress of the exercise on the screen. It is important to alert your doctor to any problems during the examination, especially chest pain and nausea. The whole examination usually does not take longer than 30 minutes, during the treatment procedure (balloon dilation - "angioplasty") within 60 minutes.

Possible complications associated with performance

In a very small percentage of cases, complications can occur, but they are immediately recognized and properly treated.
Death: on catheter examination is absolutely exceptional, the reported frequency is less than 1 patient out of a thousand treated.
Complications associated with the administration of a contrast agent include the possibility of an allergic reaction with rash, itching, rarely with a decrease in blood pressure and the need for medical intervention. In patients with known renal disease and impaired renal function (especially in diabetics), administration of a contrast agent may lead to impaired function, rarely requiring dialysis.
Groin complications: Bleeding with subsequent bruising (hematoma), which disappears after a few days. In about 1% of patients, bleeding is complicated by the formation of the so-called pseudoaneurysm - it is a blood flow that communicates with an unclosed vessel. This complication is diagnosed by ultrasound examination and can be treated with ultrasound probe pressure for approx. 15-30 min. In case of failure, the pseudoaneurysm can be closed with a special glue, and only a surgical revision of the groin is required. This is necessary if there is another complication - greater communication between the artery and vein (fistula, fistula).
Other complications: Rhythm disorders, which can occur after coronary arteries with a contrast agent, can be managed with medication, and can occasionally require an immediate electric shock (defibrillation), which cancels this arrhythmia.
Rarely, the femoral artery can be injured by a catheter, the nerves at the injection site can be injured, which the patient feels like tingling, possibly pain in the limb, and a blood clot can enter the body (so-called embolism), which can result in a temporary loss of consciousness, loss of vision or limb pain.

Possible test results:

1.) The coronary arteries will be smooth or only with an insignificant narrowing up to 50% of the artery lumen
               - no further coronary artery intervention is required.
2.) The coronary arteries will be diffusely affected along the entire length of the artery
               - the finding is technically not possible to treat by catheterization or surgery, the patient is still treated with drugs.
3.) There will be 1, 2 (sometimes 3) significant narrowings of more than 50-70% of the artery lumen on the coronary arteries
             - the catheter will decide on the next treatment procedure (according to the patient's age, associated diseases and coronary artery disease). There are 2 possibilities:
       a.) the catheter will perform a procedure called balloon angioplasty (percutaneous coronary angioplasty - PTCA) with / without stent implantation. This procedure is performed during the examination. Another catheter will be inserted through the groin from the puncture point, at the end of which a balloon is inflated. Under X-ray control, the doctor places the balloon in the area of ​​the narrowing and inflates it for a few seconds. In most cases, an additional wire tube (so-called "stent") is implanted at the constriction at the same time, which prevents the vessel from narrowing or closing again.
       b.) in certain cases, the finding on the coronary arteries requires cardiac surgery, ie suturing of the aorto-coronary bypass (CABG).

After the end of the performance:

After the examination, it is usually directly in the catheterization room or the loader is removed from the groin immediately after returning to the ward. In the case of follow-up treatment (angioplasty), the catheter is removed 6-8 hours apart due to the administration of anticoagulants. After withdrawing the introducer, the injection site is compressed manually or with the help of special instruments for about 10-15 minutes so that the vessel closes and major bleeding is prevented. The groin can also be "closed" with a special cap implanted in a vessel in the catheterization room.
After the bleeding has stopped, the elastic bandage of the groin is loaded with a load of "sandbag" for 5-10 hours. During this time, the injured site of the artery closes. It is necessary to keep the bed quiet, lying on your back with the lower limb outstretched on the injection side to prevent complications in the groin (bleeding with bruising, pain). After the examination, it is possible to drink and eat, it is advisable to drink plenty of fluids to flush the contrast medium through the kidneys.

Permanent pacemaker implantation is a small surgical procedure that is performed under local anesthesia in a pacemaker chamber under X-ray control. During the procedure, an ECG is continuously scanned with the possibility of immediate intervention in the event of any complication. The patient is conscious throughout the operation, he can communicate with the operating doctor. In case of pain, the patient is given pain medication. You must not eat, drink or smoke for 6 hours before the procedure. If you have a denture, take it out. The nurse at the ward will insert a cannula into your vein and prepare the operating field (shave) according to the ward's habits. You will be sterilized in the pacing room, after local anesthesia of the skin and subcutaneous tissue, the doctor will puncture or prepare a cephalic or subclavian vessel and insert an electrode into the heart via the venous system. After fixing the electrode in the heart muscle, a short subcutaneous pocket under which the pacemaker is operated is created under the collarbone. After the procedure, you will be advised to rest 24 hours on your back on the bed so that the electrodes do not come loose.
A pacemaker is a small electronic device with its own power source (battery) that is implanted under the skin under the left or right collarbone. It consists of a metal unit (battery and elements with a stimulator program), to which 1 to 2 probes (electrodes) are connected according to the type of stimulator, which connect the source with the right heart compartments. The electrode conducts electrical impulses from the source to the heart and also senses the electrical activity of the heart, thus enabling the correct coordination of the heart's action. Different types of stimulators are distinguished according to which heart compartment the electrode is located in. Atrial pacemakers with atrial lead, ventricular pacing with right ventricular lead, two-cavity atrial and right ventricular lead, and biventricular pacemakers with atrial, right ventricular, and left ventricular electrodes. The type of pacemaker that will be implanted in you depends on the type of heart rhythm disorder. Biventricular pacing is used to treat some patients with chronic heart failure.

Risk

Although this is a routine exercise, a very small percentage of complications can occur. The most common of these are:
Rhythm disorders, which can occur when the muscle is irritated by the electrode - drugs can be managed, they can occasionally require an immediate electric shock (defibrillation), which cancels this arrhythmia. Bleeding from a blood vessel injury (with a bruise that disappears after a few days), injuries to cardiac structures (valves or heart walls) when inserting the electrode, nerve damage, can rarely occur blood clot formation with possible release and formation pulmonary embolism. Surgical wound infection with the need for antibiotic therapy. In very rare cases, electrical impulses (other than heart pacing) may also irritate the diaphragm, which manifests itself in a hiccup. This condition either resolves spontaneously, or the lead must be relocated or the stimulator reprogrammed. A subclavian vein puncture may occur lung injury (pneumothorax = penetration of air into the pleural cavity, which must be aspirated in collaboration with the surgeon). It is a rare complication injury to the artery or lymphatic system with the penetration of blood or lymph into the pleural cavity. Allergic reaction to a local anesthetic with a rash, itching, rarely with a decrease in pressure with the need for medical intervention.

Home

If some of your questions have not been answered by this text, we will be happy to discuss them with you in person at our next meeting, or you can consult us at 224434964.

Summary

Atrial fibrillation is a disease in which the heart beats irregularly and often very quickly. It is therefore a disorder of the heart rhythm - arrhythmia. Atrial fibrillation is the most common heart rhythm disorder, its incidence increases with age, affecting up to 10% of individuals over the age of 70. This disease sometimes has no symptoms, but it can manifest itself in feelings of irregular and unpleasant palpitations, shortness of breath, general fatigue and weakness. Atrial fibrillation is diagnosed from an ECG. There are basically two risks from an arrhythmia. First, the heart can become exhausted and fail with rapid activity. Second, there is a risk of a blood clot forming in the heart, which can cause a stroke. There are several ways we try to restore and maintain a normal heart rhythm. We have drugs, electrical cardioversion and catheterization services available. Medicines to reduce blood clotting ("thinning") are also a very important and integral part of treatment.

What is atrial fibrillation?

The heart consists of four compartments, two atria and two ventricles. In a normal, so-called sinus rhythm, both atria first contract at the same time to expel blood into the ventricles, then both ventricles contract simultaneously and expel blood throughout the body. This coordinated cardiac activity is controlled by electrical impulses propagating from the right atrium. Atrial fibrillation is a disorder of the heart rhythm - arrhythmia - caused by abnormal electrical activity of the atrial muscle cells, in which the atria and consequently the heart chambers contract chaotically. This creates an irregular heartbeat, in which the heart can also beat very quickly.

Atrial fibrillation can take many forms. The first is the so-called paroxysmal form. Episodes of arrhythmias lasting up to seven days occur. Another form is a persistent arrhythmia, which either lasts for more than a week or even does not stop on its own and must be stopped by treatment. There are also situations where the arrhythmia is left permanent (eg if the patient does not have any problems), then we call it permanent.  

Within the natural course of the disease, the arrhythmia tends to gradually progress from paroxysmal to persistent and then to permanent form.

What is atrial flutter?

Atrial flutter is an arrhythmia similar to atrial fibrillation. The activity of the atria is a bit less chaotic, with electrical impulses circling in certain paths. Sometimes atrial flutter and atrial fibrillation flow freely. The risk factors for the development of atrial flutter, symptoms and treatment are very similar to those for atrial fibrillation. The following text is therefore valid for both arrhythmias.

What causes an arrhythmia?

Sometimes atrial fibrillation has a clear transient cause (lack or excess of minerals in the blood, acute inflammation, increased thyroid function, condition after heart surgery, etc.), but in most cases such a cause cannot be identified. Arrhythmia is most often caused by the scarring of the atrial wall that comes with age - it is comparable to wrinkles on the skin. The process is accelerated in patients with heart failure (patients after myocardial infarction, with heart valve defects) and in individuals with high blood pressure, chronic kidney disease, diabetes. Atrial fibrillation is also more common in overweight / obese people who drink excessively and in individuals with sleep apnea. 

How do I know I have an arrhythmia?

The symptoms of atrial fibrillation can vary. Some individuals are unaware of it (arrhythmia is then detected by chance, for example during a preventive examination or ECG examination for other reasons). Others have symptoms that include: fast, irregular heartbeat or skipping, shortness of breath, general weakness and fatigue, sweating, and possibly chest pain, feelings of fainting, and loss of consciousness. 

Atrial fibrillation is diagnosed from an ECG. It can be captured on an ECG recorded during a medical examination, or on a recording of a 24-hour Holter ECG examination or wearable electronics. Irregular heartbeat can also be detected by palpation of the artery on the wrist, but it can also be a different arrhythmia. If you experience an irregular heartbeat, ask your doctor to record an ECG.

What are the consequences of an arrhythmia?

There are basically two risks from an arrhythmia. The heart may become exhausted by rapid activity and heart failure may develop. That's why we try to reduce the number and duration of arrhythmia episodes, and always control medication so that the heart doesn't beat too fast.

Another risk is the development of a stroke. The atria of the heart tend to contract irregularly and incompletely. The flow of blood that is expelled from the healthy atrium during a normal rhythm slows down. This can lead to a blood clot that threatens to travel into the bloodstream. A blood clot with blood can enter the arteries that supply various organs. Clogging of the artery will cause a breakdown in the blood supply to the organ, with possible serious consequences. Among the most serious is a blockage of a blood vessel in the brain causing a stroke (stroke) and thus often irreversible damage in terms of movement disorders, speech and the like, sometimes life-threatening. For this reason, anticoagulant therapy is part of the treatment of atrial fibrillation. These are "blood-thinning" medicines that prevent blood clots from forming and thus reduce the risk of stroke.

How is arrhythmia treated?

The treatment of atrial fibrillation is very individual and should be literally tailored to each patient. Therefore, the cooperation between doctor and patient is very crucial. We do not try to eliminate the arrhythmia in all patients. In some of them, the difficulties resulting from the presence of the arrhythmia are minimal and we focus mainly on heart rate correction (so-called frequency control), prevention of complications and treatment of associated diseases. In other patients, on the other hand, each arrhythmia attack is unpleasantly perceived and the treatment is aimed mainly at reducing the frequency and duration of arrhythmia episodes (so-called rhythm control). In many cases, the treatment proceeds step by step. It is important to mention that the arrhythmia itself does not directly endanger life and rhythm control does not prolong life. Therefore, we decide to control the rhythm based on the presence of symptoms resulting from the presence of the arrhythmia. 

Basically frequency control are drugs that slow the heart rate (how many times the heart beats per minute) in arrhythmias, especially beta-blockers, or digoxin and calcium channel blockers. In some cases, their combinations. The goal is a resting heart rate in the range of approximately 70 to 110 / min.

Within rhythm control we have several procedures available. 

The first are drugs that stabilize the electrical activity of the heart, so-called antiarrhythmics (amiodarone, propafenone). If the heart is otherwise working well, it is best to use propafenone. If atrial fibrillation episodes are uncommon, it can only be used during a running arrhythmia. This method is called "pill in the pocket". If the episodes recur frequently, we try to prevent this with daily preventive medication. Amiodarone can also be used in cases of impaired heart function, ie heart failure. This drug is clearly the most effective, but it can have a number of side effects with long-term use. Amiodarone is always taken regularly, once a day, it cannot be used in the "pill in your pocket" mode.

If the arrhythmia fails to stop the medication, we proceed to electrical cardioversion. This is a procedure that takes place under a short, several-minute anesthesia. During this, an electric shock is applied to the chest area using two electrodes, which usually sets a normal heart rhythm. If the arrhythmia episode is longer than 48 hours or its duration is unclear, we cannot end it immediately. This is because a longer duration of the arrhythmia gives you enough time to form a blood clot in the atrium. There is a risk that when the arrhythmia is actively terminated (electrical or drug cardioversion), the clot will be released into the circulation and cause a stroke. It is therefore necessary to postpone the attempt to end the arrhythmia for at least 3 weeks. During these three weeks, the patient takes blood thinners that dissolve any clot. Cardioversion can then be performed. If the patient's condition does not allow us to wait three weeks, we can rule out the presence of a clot in the heart by esophageal echocardiography. This is a specific echocardiographic examination, where a probe - a tube with a diameter of about 1 cm is inserted through the mouth into the esophagus, from where you can use ultrasound to examine the heart inside the chest and thus rule out the presence of a clot in the left atrium. If there is no clot, cardioversion can be performed. 

In some cases, such as if the arrhythmia returns after electrical cardioversion or we are unable to control the medication, it is possible to perform a procedure during short hospitalizations to prevent new episodes. This is the so-called isolation of the pulmonary veins. Catheters (special tubes) are inserted into the heart by injection of the groin. There, radio frequency energy (by heating the end of the catheter) or a freezing balloon creates scars that separate, thus isolate, the pulmonary vein outlet areas into the left atrium. These areas are the site of the most common atrial fibrillation. The procedure usually lasts 2-4 hours and takes place under local anesthesia. A similar procedure can be performed on most patients with atrial flutter. Catheterization therapy is approximately as safe as drug therapy, but is significantly more effective.

Another important part of therapy is anticoagulation (reduction of blood clotting). A blood clot released from a chaotically contracting hall can cause a stroke. We try to prevent this by preventive "dilution" of blood - anticoagulant therapy. The risk of a blood clot is not the same in every patient, it increases with age, it is higher in patients with diabetes, high blood pressure, in patients who have already had a stroke, and in patients after a heart attack or with heart failure. Anticoagulant therapy is not required in any patient at low risk of stroke. Your doctor will tell you if you need anticoagulant treatment. 

A general feature of all anticoagulants is that they increase the risk of bleeding. This is usually easier bruising, slower cessation of bleeding, for example, abrasions or nosebleeds. Exceptionally, more severe bleeding may occur. It is necessary to think about the temporary discontinuation of anticoagulant therapy before the planned surgery, including, for example, tooth tearing. Always consult this with your surgeon and your cardiologist.

Warfarin is the drug that is currently fully covered by health insurance for all patients with atrial fibrillation indicated for anticoagulant therapy. Its effectiveness should be monitored by regular blood sampling. Initially, withdrawals are more frequent, when the dose is well set, withdrawals once every 4 to 6 weeks are sufficient. We monitor the degree of "dilution" using the INR (international normalized ratio), this test is also called Quick's, popularly quick, "kvik". The INR value should be between 2 and 3. If the value is less than 2, the blood is not diluted enough; if, on the contrary, the value is higher than 3, the patient is at increased risk of bleeding. 

Some vegetables (those high in vitamin K) can dampen the effect of Warfarin. Therefore, it was previously recommended that patients taking Warfarin reduce the amount of vegetables in their diet. This is no longer the case today, but it is important that the representation of vegetables in your diet is balanced in the long run. If you are taking Warfarin, ask us for more information on the food parties involved. We will be happy to advise you.

There are other drugs used in patients with atrial fibrillation to thin the blood - a group called NOACs - new oral anticoagulants (Pradaxa®, Eliquis®, Lixiana®, Xarelto®). It protects against stroke as effectively as Warfarin, and their effect does not need to be monitored by blood sampling. Their use is not possible in patients with mechanical valve replacement. 

Can I somehow alleviate the effects of the arrhythmia, or reduce the likelihood that it will return?

Yes! A healthy lifestyle can significantly reduce the likelihood that the arrhythmia will return. In addition, it is a good prevention against the development of other diseases.

• Eat healthy. Lots of fruits and vegetables, don't salt. Choose poultry and fish, beef and pork only 2-3 times a month. Avoid greasy and fried foods, prefer baking and stewing over frying. Don't drink sweet drinks, choose wholemeal bread.

• Do sports regularly. We recommend 30 minutes of activity at least 5 days a week. Choose fitness (aerobic) exercises that suit your physical capabilities - faster walking or running at a moderate pace, cycling or swimming. Every movement counts, prioritize the stairs before the elevator, walk before driving, etc.

• Quit smoking. If you have tried and stopped smoking, get help from a tobacco addiction treatment center. They are usually affiliated with lung clinics, in our teaching hospital you can order on tel. 224436646.

• If you are overweight, lose weight. Being overweight, as well as high cholesterol and diabetes, significantly increases the risk of developing and maintaining atrial fibrillation.

• Limit alcohol intake. Alcohol excesses or regular drinking of large amounts of alcohol increases the risk of atrial fibrillation. .

• Have your thyroid function checked in a laboratory.

• If you are snoring at night, or if you notice breathtaking, breathing breaks during your sleep, or you are overly drowsy during the day, and especially if you are overweight with these symptoms, ask your GP to arrange an examination to rule out sleep apnea.

• Keep your blood pressure under control. If you are already being treated for high blood pressure, it is advisable to have a sphygmomanometer at home, use it regularly and record in time that your blood pressure treatment is not optimal. In the long run, blood pressure values ​​above 135/85 mmHg in domestic measurements mean insufficient blood pressure and increase the risk of developing not only atrial fibrillation, but also other cardiovascular diseases such as myocardial infarction, stroke or heart failure.

• Find your cardiologist. Every patient with atrial fibrillation should see a heart disease specialist regularly for atrial fibrillation because of the increased risk of other heart diseases. 

• Take the recommended treatment regularly. Blood thinning treatment is especially important. 

• If you are taking Warfarin, check your INR regularly. Otherwise, your blood may not be sufficiently diluted even if you take the medicine regularly. This means that you are not protected against the risk of stroke. The other extreme is Warfarin overdose, which puts you at high risk for life-threatening bleeding.

MUDr. Hnátová Hana, 25.11.2020/XNUMX/XNUMX

Our workplace is equipped with the latest technologies used in the diagnosis and treatment of heart disease. The workplace includes 3 fully equipped catheterization rooms and 1 room for arrhythmological interventions. Extras include intravascular ultrasound with virtual histology, a system for three-dimensional electroanatomical mapping of the heart, and modern echocardiography devices for a full range of imaging, including three-dimensional cardiac imaging.

• Annual Report 2011 (524,19 KB)
• Annual Report 2016 (694,45 KB)

• Science and teaching
  
  
• Stages
  
  
• Publications
  
  
• Social activities

We pay great attention to research activities, as evidenced by the high number of publications in domestic and foreign journals each year. Our doctors actively participate in important foreign congresses in North America, Europe and Asia with their lectures or posters. Most of our research projects focus on interventional cardiology, acute coronary care, hypertrophic cardiomyopathy, echocardiography and valve defects, and arterial thrombosis research.

Both undergraduate and postgraduate teaching takes place at the Cardiology Clinic. As part of undergraduate teaching, we teach cardiology to students of the 2nd Faculty of Medicine. In this study, students get acquainted with the basics of cardiovascular disease at the patient's bedside, as well as with the basic invasive and non-invasive examination methods. The lectures present a comprehensive view of cardiovascular diseases; from coronary heart disease, myocardial infarction, to valve defects to arrhythmology. Due to the scope of the whole issue of cardiovascular diseases, which goes beyond the time possibilities of internships, students have the opportunity to gain deeper knowledge in the field within the elective course Basics of Clinical Cardiology.

Our workplace is accredited for postgraduate preparation before postgraduate certification in cardiology and also within the granting of functional licenses in individual examination methods. 

In the evaluation of the quality of teaching by students of the 2nd Medical Faculty of Charles University, our workplace was evaluated as the best among clinical disciplines.

Internships in the echocardiography laboratory

Transthoracic echocardiography

Internship for beginners in echocardiography and doctors working in the echocardiography laboratory.

Duration 3-6 weeks, dates in agreement with the trainer.

Supervisor: Prof. MUDr. Veselka Josef, CSc.

Price 3 weeks 12.000 incl. VAT, 6 weeks, price 18 000 CZK incl. VAT

Esophageal echocardiography

Internship for doctors working in an echocardiography laboratory.

Supervisor: Prof. MUDr. Veselka Josef, CSc.

Duration 2 weeks, dates in agreement with the trainer. Price 10 000 CZK incl. VAT

It is possible to individually agree on another scope of the internship.

You will find the procedure for concluding an internship contract <a href="https://cdn.shopify.com/s/files/1/1932/8043/files/Odstoupeni_od_smlouvy_EN.pdf?v=1595420299" data-gt-href-en="https://en.notsofunnyany.com/">HERE</a>

Czech articles:

Alan D, Vejvoda J. Pulmonary catheter - to use or not to use? Cor Vasa 2010; 52: 458–60.

Durdil V. Ventricular arrhythmias and sudden cardiac death in hypertrophic cardiomyopathy. Cor Vasa 2010; 52: 441–446.

Fiedler J, Linhartová K, Hájek P, Malý M, Zemánek D, Adlová R, Veselka J. Balloon valvuloplasty of the aorta in high - risk patients with aortic stenosis. Cor Vasa 2010; 52: 413-7.

Fiedler J. The role of echocardiography in the diagnosis of infectious endocarditis. Postgrad Med 2010; 12 (Suppl.1): 16-21.

Fiedler J. Diagnosis and treatment of non-compact cardiomyopathy. Cor Vasa 2010; 52: 403-4.

Hájek P. Timing and selection of the method of revascularization in acute coronary syndrome without elevations of the ST region with multiple coronary artery disease. Cor Vasa 2010; 52: 447–52.

Plasma protein A associated with pregnancy in the pathophysiology, diagnosis and prognosis of ischemic heart disease. Cor Vasa 2010; 52: 453–7.

Linhartová K, Malý M, Adla T, Veselka J. Catheter implantation of aortic valve - multimodal imaging. Cor Vasa 2010; 52: 470-1.

Linhartová K. Diagnosis and treatment of the most common form of restrictive cardiomyopathy: cardiac amyloidosis. Cor Vasa 2010; 52: 393-6.

Malý M, Šramko M, Zimolová P, Stanka P, Hájek P, Zemánek D, Martinkovičová L, Tesař D, Veselka J. Risk of pseudoaneurysm in patients after elective angiography - analysis of 498 consecutive patients. Cor Vasa 2010; 52: 418-24.

The catheter closure of the ductus arteriosus patens Amplatz 's ductal occluder of the new generation in an adult patient. Cor Vasa 2010; 52: 467-9.

Malý M, Marinov I, Oravec M, Veselka J. What an interventional cardiologist must know about platelets. Cardiol Rev 2010; 12: 134-7.

Hypertrophic obstructive cardiomyopathy affecting both chambers of the heart. Cor Vasa 2010; 52: 193-4.

Porazíková K, Tomašov P, Adla T, Linhartová K. Catheterization cap of coronary fistula. Cor Vasa 2010; 52: 465-7.

Infectious endocarditis of the aortic valve: extensive abscess in the aortic root and reconstruction by the aortic homograft. Postgrad Med 2010; 7: 776-7.

Riedlbauchová L, Krijtová H, Marusič P, Durdil V, Janoušek J, Veselka J. There is no syncope as a syncope or what is ictal asystole. Cor Vasa 2010; 52: 461-5.

Riedlbauchová L. Tachycardia-induced cardiomyopathy. Cor Vasa 2010; 52: 397-8.

Riedlbauchová L. Infection of stimulation systems / ICD or the growing problem of the 21st century? Postgrad Med 2010; (Suppl.1): 22-28.

Veselka J. Trends in the diagnosis and treatment of infectious endocarditis - the end of some myths. Postgrad Med 2010; 12: Suppl. 1: 6-7.

Veselka J. From internal medicine to cardiology, from cardiology to cardiovascular medicine. Cor Vasa 2010; 52: 392.

Veselka J. Diagnosis and treatment of hypertrophic cardiomyopathy. Cor Vasa 2010; 52: 409-10.

Direct determination of venous and arterial serotonin in patients with percutaneous occlusion of persistent foramen ovale. Klin Biochemie Met 2010; 18: 19-22.

Zemánek D, Hájek P, Veselka J. Use of intravascular ultrasound in interventions on the left coronary artery trunk. Cor Vasa 2010; 52: 431-6.

Zemánek D. Dilated cardiomyopathy. Cor Vasa 2010; 52,411-412.

Zemánek D, Linhartová K. Inflammatory diseases of the heart muscle. Postgrad Med 2010; 12,59-64 (Suppl.1).

Zimolová P. Ischemic limb disease: how to do it? Diagnostic and treatment algorithm for clinical practice. Cor Vasa 2010; 52: 437-440.

Foreign articles:

Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, Mates M, Kvapil M, Kettner J, Wiendl M, Aschermann O, Slaby J, Holm F, Telekes P, Horak D, Blasko P, Zemanek D , Veselka J, Cepova J. Fluvastatin in the first therapy of acute sonary syndrome: results of the multicenter, randomized, double-blind, placebo-controlled trial (the FACS-trial). Trials 2010; 11: 61.

Sterbakova G, Vyskocil V, Linhartova K. Bisphosphonates in calcific aortic stenosis: association with slower progression in mild disease - a pilot retrospective study. Cardiology 2010; 117: 184–9.

Spacek M, Veselka J. Claudication pain in the left arm of a coronary artery bypass graft patient using crutches: Coronary subclavian steal syndrome - a case report. Int J Angiol 2010; 19: e41-e42

Tomašov P, Linhartová K, Antonová P, Adlová R, Alam D, Veselka J. Combined percutaneous treatment of atrial septal defect and pulmonic or aortic stenosis in adult patients. Arch Med Sci 2010; 6: 976-80.

Veselka J, Zemánek D, Tomašov P, Homolová S, Adlová R, Tesař D. Complications of low-dose, echo-guided alcohol septal ablation. Catheter Cardiovasc Interv 2010; 75: 546-550.

Jakabčin J, Špaček R, Bystroň M, Kvašňák M, Jager J, Veselka J, Kala P, Červinka P. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug eluting stents with or without the IVUS Guidance. Randomized controlled trial. HOME DES IVUS. Catheter Cardiovasc Interv 2010; 75: 578-83.

Hubáček JA, Staněk V, Gebauerová M, Pilipčincová A, Poledne R, Aschermann M, Skalická H, Matoušková J, Kruger A, Pěnička M, Hrabáková H, Veselka J, Hájek P, Lánská V, Adámová V, Piťha J. Lack of an association between connexin-37, stromelysin-1, plasminogen activatorinhibitor type 1 and lymhotoxin alpha genes and aute coronary syndrome in Czech caucasians. Exp Clin Cardiol 2010; 15: e52-6.

Hubacek JA, Staněk V, Gebauerová M, Pilipčincová A, Dlouhá D, Noon R, Aschermann M, Skalická H, Matoušková J, Kruger A, Pěnička M, Hrabáková H, Veselka J, Hájek P, Lánská V, Adámková V, Piťha J A FTO variant and risk of acute coronary syndrome. Clin Chim Acta 2010, Epub ahead.

Poledne R, Hubáček JA, Staněk V, Aschermann M, Matoušková J, Veselka J, Widimský P, Cífková R, Lánská V, Piťha J. Why we are not able to find the heart disease gene - apoE as an example. Folia Biologica 2010; 56: 218-22.

Zemanek D, Tomasov P, Prichystalova P, Linhartova K, Veselka J. Evaluation of the right ventricular function in hypertrophic obstructive cardiomyopathy: a strain and tissue Doppler study. Physiol Res 2010; 59: 697-702.

Zemánek D, Šváb P, Veselka J. Power Doppler myocardial contrast echocardiography in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Clin Cardiol 2010; 33: E82.

Zemánek D, Veselka J, Adla T, Šetina M, Ferda J. Uncommon cause of obstruction in the left ventricular outflow tract by a metastasis sof adenocarcinoma. Arch Med Sci 2010; 6: 981-3.

Czech abstract:

Bradáčová P, Zemánek D, Adla T, Veselka J. CT coronarography has a high negative predictive value in the evaluation of restenosis after stent implantation into the stem of the left coronary artery. XVIII Annual Congress of the Czech Society of Cardiology 16.-19.5.2010. Abstract No. 289.

Fiedler J, Linhartová K, Veselka J. Contrastive echocardiographic examination in intracardiac tumors. Cor Vasa 2010; 52: K770.

Use of CT angiography in PCI closed venous bypass. XVIII. Annual Congress of the Czech Society of Cardiology Brno 2010.

Percutaneous balloon valvuloplasty of mitral bioprosthesis in a patient at high risk of reoperation. XIX Communication. of the annual congress of the Czech Society of Cardiology 16.-19.5.2010.

Porazíková K, Linhartová K, Adla T, Kamarádová K, Segethová J, Veselka J. Pitfalls of diagnostics of restriction cardiomyopathy - light chain disease. Echodny 2010 24.-25. September, Spindleruv Mlyn.

Riedlbauchová L, Krijtová H, Durdil V, Veselka J. There is no syncope as a syncope ... - lecture at the XVIII Congress of the Czech Society of Cardiology, 19.5.2010 Brno Exhibition Grounds (abstract no.637)

Tomasov P, Minarik M, Zemanek D et al. Screening of the most common causal mutations in patients with hypertrophic cardiomyopathy Cor Vasa 2010; 52; Suppl: 185.

Zemánek D, Tomašov P, Homolová S, Veselka J. Isosorbide dinitrate in provocation of obstruction in the outflow tract of the left chamber in hypertrophic cardiomyopathy. XVIII Annual Congress of the Czech Society of Cardiology 16.-19.5.2010. Abstract No. 451.

Foreign abstracts:

Bradáčová P, Zemánek D, Adla T, Hájek P, Malý M, Veselka J. Dual-Source Computed Tomography Has a High Negative Predictive Value in the Evaluation of Restenosis after the Left Main Coronary Artery Stenting. Am J Cardiol 2010; 105: 8B.

Hajek P, Macek M Sr, Lashkevich A, Kluckova H, Hladikova M, Hansvenclova E, Maly M, Krejsova A, Veselka J. The increase of pregnancy associated plasma protein-A is directly linked to heparin administration not only to acute coronary syndrome. Eur Heart J 2010; 31 Abstract Suppl: 193

Hajek P, Macek M Sr, Lashkevich A, Kluckova H, Hladikova M, Hansvenclova E, Maly M, Krejsova A, Veselka J. Influence of Concomitant Heparin Administration on Pregnancy-Associated Plasma Protein-A Kinetics: Need for Reassessment of the Diagnostic ( Prognostic) Value in Acute Coronary Syndrome. 52nd Annual World Congress ICA 2010, University of Kentucky Lexington, Kentucky October 17-19, 2010

Maly M, Oravec M, Majek P, Reicheltova Z, Suttnar J, Veselka J, Dyr JE. Proteomic analyzes of the acute coronary syndrome patients. Eur Heart J 2010; 31 Abstract Suppl: 539

Tomašov P, Perrot A, Posch M, Veselka J. Connective Tissue Growth Factor Promoter Polymorphism in Patients with Acute Coronary Syndromes. Am J Cardiol 2010; 105: 84B.

Veselka J, Zemanek D, Tomasov P, Homolova S, Adlova R. Complications of low-dose, echo-guided alacohol septal ablation for obstructive hypertrophic cardiomyopathy. J Heart Dis 2010; 7: 61.

Veselka J, Zemanek D, Martinkovicova L, Maly M, Hajek P, Adlova R, Tesar D. Pre-PCI atorvastatin: a randomized study. J Heart Dis 2010; 7: 102.

Veselka J, Hajek P, Maly M, Zemanek D, Adlova R, Tesar D, Martinkovicova L, Tomasov P. Prediction of coronary intervention-related myocardial infarction in stable angina pectoris patiens pretreated with statins. J Heart Dis 2010; 7: 111.

Veselka J, Zemánek D, Hájek P, Malý M, Tomašov P, Tesař D. C-Reactive Protein and Balloon lschemic Time Are Predictors of Periprocedural Myocardial Infarction in Stable Angina Patients Undergoing Percutaneous Coronary Intervention. Am J Cardiol 2010; 105: 49B.

Veselka J, Zemánek D, Tomašov P. Early Complications of Low-Dose, Echo-Guided Alcohol Septal Ablation. Am J Cardiol 2010; 105: 55B.

Veselka J. Management of Acute Coronary Syndrome: Different Points of View Across the Ocean. 52nd Annual World Congress of ICA 2010, Lexington, Kentucky, 2010.

Veselka J, Zimolová P, Martinkovičová L. Comparison of Mid-Term Outcomes of Carotid Artery Stenting for Moderate versus Critical Stenosis. 52nd Annual World Congress of ICA 2010, Lexington, Kentucky, 2010.

Piťha J, Staněk V, Poledne R, Gebauerová M, Aschermann M, Skalická H, Matoušková J, Kruger A, Pěnička M, Hrabáková H, Veselka J, Hájek P. Impact of maternal and paternal history of premature myocardial infarction on the age of manifestation of acute coronary syndrome. Atherosclerosis Supplements 2010; 11: 149-150.

Zemánek D, Celerýn S, Hájek P, Malý M, Veselka J. Sodium Bicarbonate in Saline Infusion Is Worse for the Prevention of Contrast-Induced Nephropathy than Saline Infusion Alone: ​​A Randomized Single-Center Study. Am J Cardiol 2010; 105: 16B-17B.

Zemánek D, Adla T, Bradáčová P, Hájek P, Veselka J. The role of the dual-source computed tomography in the evaluation of restenosis after the left main coronary artery stenting. A comparison with coronary angiography and intravascular ultrasound. J Am Coll Cardiol 2010; 56 (Suppl B): 90.

Zemánek D, Bradáčová P, Adla T, Veselka J. The Comparison of Dual-Source Computed Tomography, Coronary Angiography and Intravascular Ultrasound in the Evaluation of Restenosis after the Left Main Coronary Artery Stenting. Eur Heart J 2010; 31,289 (Abstract Supplement).

Czech articles

Homolová S, Zemánek D, Veselka J. Stratification of sudden death risk in hypertrophic cardiomyopathy. Cor Vasa 2009; 51: 38-40.

Aortic stenosis and results of the SEAS study - does hypolipidemic treatment of patients with aortic stenosis make sense? Cor Vasa 2009; 51: 210-1.

Malý M, Marinov I, Hájek P, et al. Subacute stent thrombosis associated with high residual platelet activity. Cor Vasa 2009; 51: 817-20.

Malý M. Atherothrombosis: antiplatelet therapy. Cor Vasa 2009; 51 (Suppl. 1): 19-21.

Veselka J, Adla T. Ten reasons why a cardiologist must be interested in a CT scan of the heart. Cor Vasa 2009; 51: 9-11.

Veselka J. Nuclear storm in a glass of water. Vnitř Lék 2009; 55: 70-1.

Adla T, Neuwirth J, Veselka J, et al. Imaging of the heart by computed tomography using an instrument with two X-ray detector systems: one year of experience at the University Hospital in Motol. Interv Akut Kardiol 2009; 8: 15-8.

Veselka J, Trends in Czech Interventional Cardiology. Cor Vasa 2009; 51 (Suppl. 1): 6-8.

Veselka J, Zimolova P, Stanka P, et al. Stent implantation into major carotid artery stenoses using the protective FilterWire EZ system. Cor Vasa 2009; 51: 255-9.

Veselka J, Important recent publications in interventional cardiology and related fields. Cor Vasa 2009; 51 (Suppl.1): 3-5.

Veselka J. Risk of sudden death in patients with hypertrophic cardiomyopathy. Postgrad Med 2009; (Suppl.): 44-7.

Veselka J. Comment on the article J. Vojáček et.al. Surgical treatment of symptomatic hypertrophic obstructive cardiomyopathy, published in Cor et Vasa 2009; 51: 520-1.Cor Vasa 2009; 51: 741

Zemánek D. Contrast-induced nephropathy. Cor Vasa 2009; 51 (Suppl.): 69-72.

Foreign articles

Hajek P, Alan D, Vejvoda J, et al. Treatment of a large left main coronary artery thrombus by aspiration thrombectomy. J Thromb Thrombolysis 2009; 27: 352-4.

Linhartová K, Štěrbáková G, Racek J, Čerbák R, Porazíková K, Rokyta R. Linking soluble vascular adhesive molecule-1 level to calcific aortic stenosis in patients with coronary artery disease. Exp Clin Cardiol 2009; 14: 80-83.

Malý M, Hrachovinová I, Tomašov P, Salaj P, Hájek P, Veselka J. Patients with Acute Coronary Syndromes Have Low Tissue Factor Activity and Microparticle Count, but Normal Concentration of Tissue Factor Antigen in Platelet Free Plasma-a Pilot Study. Eur J Haematol 2009; 82: 148-53.

Malý MA, Hadačová I, Hájek P, Zemánek D, Veselka J. High-residual platelet activity despite dual antiplatelet treatment associated with subacute stent thrombosis. Cent Eur J Med 2009; 4: 119-24.

Sobotková A, Mášová-Chrastinová L, Malý M. Antioxidants change platelet responses to various stimulating events. Free Radic Biol Med 2009; 47: 1707-14.

Kotlín R, Reicheltová Z, Malý M, et al. Two cases of congenital dysfibrinogenemia associated with thrombosis - Fibrinogen Praha III and Fibrinogen Plzeň. Thromb Haemost 2009; 102: 479–486.

Riedlbauch L, Brunken R, Jaber WA, et al. The impact of myocardial viability on the clinical outcome of cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2009; 20: 50–7.

Sonne K, Patel D, Riedlbauchova L. Pulmonary vein antrum isolation, atrioventricular junction ablation, and antiarrhythmic drugs combined with direct current cardioversion: survival rates at 7 years follow-up. J Interv Card Electrophysiol 2009; 26: 121–6.

Veselka J, Černá D, Zimolová P, et al. Feasibility, Safety and Early Outcomes of Direct Carotid Artery Stent Implantation with Use of the FilterWire EZ Embolic Protection System. Catheter Cardiovasc Interv 2009; 73: 733-8.

Veselka J, Zemánek D, Duchoňová R, Tomašov P, Linhartová K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Ultra-low dose of alcohol (1 ml) is still effective. Heart Vessels 2009; 24: 27-31.

Veselka J, Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: Is it Safe? Catheter Cardiovasc Interv 2009; 74: 520-1.

Veselka J, Zemánek D, Hájek P, et al. Effect of Two-Day Atorvastatin Pre-Treatment on the Incidence of Peri-Procedural Myocardial Infarction Following Elective Percutaneous Coronary Intervention: A Single-Center, Prospective, and Randomized Study. Am J Cardiol 2009; 104: 630-3.

Veselka J, Zemánek D, Fiedler J, Šváb P. Real-time myocardial contrast echocardiography for echo-guided alcohol septal ablation. Arch Med Sci 2009; 5: 271-2.

Čurila K, Benešová L, Veselka J. Low prevalence and variable clinical presentation of troponin I and troponin T gene mutations in hypertrophic cardiomyopathy. Genet Test Mol Biomarkers 2009; 13: 647-50.

Czech abstract

Antonová P, Linhartová K. Dysfunction of the systemic right ventricle in patients after atrial reduction for transposition of large arteries - etiopathogenesis, diagnostics, new findings on treatment. Cor Vasa 2009; 51: 76.

Preliminary results of examination of patients after percutaneous coronary intervention of the left coronary artery by CT coronarography (pilot study) XVII. annual congress of the Czech Society of Cardiology 10.-13. May 2009. Abstract No. 198.
Fiedler J, Linhartová K, Veselka J. Descending aortic thrombi in esophageal echocardiography. Cor Vasa 2009; 51: K643.

Hajek P, Macek M SR, Adlova R, et al. PAPP-A / proMBP in patients with normal coronary angiogram. XVII. annual congress of the Czech Society of Cardiology 10-13. May 2009. Abstract No. 405.

Hašková M, Matyščáková B. Selected echocardiographic parameters determined by the portable device PHILIPS OptiGo nurse - degree of agreement with the results of the doctor with the standard echocardiographic device Cor Vasa 2009; 51: 650.

Porazíková K, Štěrbáková G, Kovalová S, Štětka F, Čerbák R, Linhartová K. Hypertrophy of the left ventricle and angina pectoris after aortic valve replacement XVII. annual congress of the Czech Society of Cardiology 10.-13. May 2009. Abstract No. 523.

Tomasov P, Perrot A, Zemanek D et al. Analysis of the NEBL gene for the sarcomere protein nebulette in a group of patients with hypertrophic cardiomyopathy. XVII Annual Congress of the Czech Society of Cardiology 10.-13. May 2009. Abstract No. 188.

Tomasov P, Perrot A, Hajek P et al. Analysis of functional polymorphism in the promoter of the connective tissue growth factor gene in patients with acute coronary syndromes. XVII Annual Congress of the Czech Society of Cardiology 10.-13. May 2009. Abstract No. 632.

Obstruction in hypertrophic cardiomyopathy. XVII. annual congress of the Czech Society of Cardiology 10.-13. May 2009, Abstract No. 420.

Foreign abstract

Linhartova K, Sterbakova G. Bisphosphonate treatment found associated with slower progression of calcific aortic stenosis. Eur J Echocardiography 2009; 10: 2: 48.

Tomasov P, Perrot A, Zemanek D, et al. NEBL encoding the cardiac Z-disc protein nebulette as a novel disease gene for cardiomyopathies. Eur Heart J 2009; 30: 540.

Veselka J, Zimolova P, Stanka P, et al. Feasibility, safety and early outcomes of direct carotid artery stent implantation with use of the FilterWire EZ Embolic Protection System. Catheter Cardiovasc Interv 2009; 73: S22.

Veselka J, Zemánek D, Tomašov P, Homolová S, Adlová R. Low-dose alcohol septal ablation for obstructive hypertrophic cardiomyopathy is effective and safe. International College of Angiology 51st Annual Worls Congress, Beijing, China, Abstract book, p. 75.

Veselka J, Zemanek D, Hajek P, et al. Effect of two-day atorvastatin pre-treatment on the incidence of peri-procedural myocardial infarction following elative percutaneous coronary intervention. Eur Heart J 2009; Suppl.

Veselka J, Zemánek D, Hájek P, et al. Effect of Two Day Atorvastatin Pre-Treatment on the Incidence of Peri-Procedural Myocardial Infarction Following Elective Percutaneous Coronary Intervention: A Single-Center, Prospective, and Randomized Study. Am J Cardiol 2009; 104: 630-3.

Hubáček JA, Adámková J, Veselka J. FTO polymorphism is associated with myocardial infarction. Atherosclerosis 2009; 207: 8.

Zemánek D, Tomašov P, Homolová S, Linhartová K, Veselka J. Sublingual isosorbide dinitrate for detection of obstruction in hypertrophic cardiomyopathy. Eur Heart J 2009; 30,551.

Books and chapters in books

Veselka J, Linhartová K, Zemánek D et al. Cardiomyopathy. Galén 2009.  

Veselka J. Ischemic heart disease. Basic information for patients. FAMA 2009

Černý V, Matějovič M, Dostál P. Selected recommended procedures in intensive care245 s .: Linhartová K: Infectious endocarditis.s. 57-64. Maxdorf 2009.

Riedlbauchová L, Kautzner J. Arrhythmias and heart failure - chapter in the book: Vojáček J and Kettner J. Clinical Cardiology, 2009, Nukleus Hradec Králové. pp. 397–402.

Czech articles

Duchonal R, Veselka J, Linhartová K. Balloon aortic valvuloplasty: a forgotten method or hope for high-risk seniors? Cor Vasa 2008; 50: 163-6.

Fiedler J. Functional mitral regurgitation. KF 2008; 6: 22-4.

Fiedler J, Linhartová K, Blaško P, Choi-Širůčková J, Černá D, Šetina M, Mošna F, Veselka J. Three-dimensional echocardiography in the diagnosis of fast-moving intracardiac formations. Cor Vasa 2008; 50: 76-82.

Cardiovascular risk profile of patients with coronary heart disease and aortic stenosis or sclerosis Cor Vasa 2008; 50: 104-108.

Linhartová K. Trends in the diagnosis and treatment of the most common valve defects. S 4 in: Linhartová K, et al. The most common valve defects. KF 2008; 6: 1-32.

Linhartová K. Etiology of aortic stenosis and chances of drug treatment. S 5-7 in: Linhartová K, et al. The most common valve defects. KF 2008; 6: 1-32.

Ferda J., Linhartová K. Imaging of the aortic valve using computed tomography and magnetic resonance imaging. S 14-17 in: Linhartová K, et al. The most common valve defects KF 2008; 6: 1-32.

Tomašov P. Genetics of hypertrophic cardiomyopathy. KF 2008; 6: 5-8.

The importance of multidetector CT in clinical cardiology. Cor Vasa 2008; 50: 83-5.

Veselka J, Duchoňová R, Zemánek D. Combination of antegrade and retrograde recanalization of chronically closed coronary artery. Cor Vasa 2008; 50: 11.

Veselka J, Červinka P. Standards for catheterization procedures in ischemic heart disease. Cor Vasa 2008; 50: K86-9.

Veselka J. Rediscovered balloon valvuloplasty in patients with calcified aortic stenosis. KF 2008; 1: 8-11.

Veselka J. Interventional Cardiology 2008. Cardiol Rev 2008; 10 (Suppl): 23-7.

Veselka J. www.kardiomyopatie.cz or how to get closer to patients with hypertrophic cardiomyopathy. KF 2008; 2: 4.

Veselka J. HCM - clinical picture and course of the disease. KF 2008; 2: 21-23.

Veselka J. Therapy of hypertrophic cardiomyopathy. KF 2008; 2: 31-4.

Veselka J. Finding the optimal therapy for carotid disease will probably be a task for future generations of doctors. Cor Vasa 2008; 50: 320-1.

Mikulová J, Veselka J, Adla T, Charouzek J. Anomalous distance of the ramus circumflexus from the right Valsalva sinus. Cor Vasa 2008; 50: 352.

Veselka J. Some aspects of the influence of marathon running on the cardiovascular system. Cor Vasa 2008; 50: 393-5.

Veselka J. Nuclear Cardiology: Indispensable or Indispensable? Internal Medicine 2008; 54: 945-7

Zemánek D. Ischemic mitral regurgitation: mechanism, evaluation and treatment. KF 2008; 6: 18-21.

Zemánek D. Left ventricular hypertrophy in aortic stenosis - compensatory reaction or pathological adaptation? KF 2008; 6: 11-13.

Zemánek D. Pathophysiology of hypertrophic cardiomyopathy. KF 2008; 6: 17-20.

Zemánek D. Hypertrophic cardiomyopathy - diagnosis. KF 2008; 6: 23-27.

Diseases of the venous system DK - chronic venous insufficiency. Medical Letters 2008; 10: 23-24.

Foreign articles

Hajek P, Macek M Sr. Pregnancy associated plasma protein a as a quick and sensitive biomarker in early phase of acute coronary syndrome. Am J Cardiol 2008; 102: 954.

Hajek P, Alan D, Vejvoda J, Linhartova K, Skapa P, Hajsmannova Z et al. Treatment of a large left main coronary artery thrombus by aspiration thrombectomy. J Thromb Thrombolysis 2008; Mar 10 [Epub ahead of print]

Hájek P, Macek M, Hladíková M, Houbová M, Alan D, Durdil V, Fiedler J, Malý M, Ošťádal P, Veselka J, Krebsová A. Pregnancy-associated plasma protein A and proform eosinophilic major basic protein in the detection of different types of coronary artery disease. Physiol Res 2008; 57: 23-32.

Ferda J, Linhartová K, Kreuzberg B. Comparison of aortic valve calcium content in bicuspid and tricuspid stenotic aortic valve using non-enhanced 64-detector-row-computed tomography with prospective ECG-triggering. Eur J Radiol 2008; 68: 471-475.

Linhartova K, Veselka J, Sterbakova G, Racek J, Topolcan O, Cerbak R. Parathyroid hormone and Vitamin D levels are independently associated with calcific aortic stenosis. Circ J 2008; 72: 245-50.

Linhartova K. Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis. Heart. 2008; 94: 508.

Malý M, Hrachovinova I, Tomašov P, Salaj P, Hájek P, Veselka J. Patients with Acute Coronary Syndromes Have Low Tissue Factor Activity and Microparticle Count, but Normal Concentration of Tissue Factor Antigen in Platelet Free Plasma-a Pilot Study. Eur J Haematol 2008 (in press).

Posch MG, Thiemann L, Tomasov P, Veselka J, Cardim N, Garcia-Castro M, Coto E, Perrot A, Geier C, Dietz R, Haverkamp W, Oczelik C. Sequence analysis of myozenin 2 in 438 European patients with familial hypertrophic cardiomyopathy. Med Sci Monit 2008; 14: CR372-4.

Jakabčin J, Bystroň M, Špaček R, Veselka J, Kvašňák M, Kala P, Malý J, Červinka P. The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. J Thromb Thrombolysis 2008; 26: 154-8.

Veselka J, Zimolová P, Černá D, Stanka P, Tomek A, Šrámek M. Carotid Artery Stenting in Asymptomatic and Surgically High-Risk Patients: Single-Center, Single-Operator Results. Int J Angiol 2008; in press.

Veselka J, Zemánek D, Duchoňová R, Blaško P, Adla T, Tesař D, Neuwirth J. Coronary angiography and dual-source computed tomography are complementary methods in diagnosis of significant stenosis of the right coronary artery originating from the left aortic sinus. Cent Eur J Med 2008; 3: 111-114.

Tůma S, Tesař D, Veselka J, Neuwirth J. Plaque imaging: clinical implications and use of invasive methods. J Appl Biomed 2008; 6: 1-14.

Zemánek D, Veselka J, Chmelová R. Infective endocarditis after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Int Heart J 2008; 49: 371-5.

Czech abstract

Celerýn Š, Zemánek D, Bradáčová P, Porazíková K, Durdil V, Pavliňák V, Veselka J et. al. Prevention of contrast nephropathy in elective catheter examinations. Abstract of the 2008th CCP Annual Congress 6: XNUMX.

Fiedler J. Non-compact cardiomyopathy - current knowledge from our cardio center.
Cor Vasa 2008; 50: K129-130.

Fiedler J. The width of the carotid intima-media complex does not differ in patients with aortic stenosis and other valve defects. Abstract of the 2008th CCP Annual Congress 12: XNUMX.

Hajek P, Macek Sr. M, Ošťádal P, Hansvenclová E, Hladíková M, Malý M et al. Significance of the interval “Pain - Collection” to the level of the Pregnancy-associated plasma protein-A / proform of eosinophil major basic protein complex in acute coronary syndrome. Cor Vasa 2008; 50: S17.

Pavliňák V, Fiedler J. Spontaneous left ventricular echocontrast. Cor Vasa 2008; 50: K136-7.

Veselka J, Fiedler J. Catheter closure of atrial septal defect and foramen ovale patens. Cesk Slov Neur N 2008; 71: S24-5.

Veselka J, Černá D, Zimolová P, Duchoňová R, Šramko M, Tomek A, Šrámek M. Direct implantation of a stent into carotid stenoses is feasible, safe and effective. Ces Slov Neur N 2008; 71: S25. 

Zemánek D, Veselka J, Tomašov P, Sedláková M, Linhartová K. Right ventricle in hypertrophic cardiomyopathy: tissue Doppler imaging and strain. Cor Vasa; 29.

Detection of obstruction in hypertrophic cardiomyopathy. Cor Vasa 2008; 50; K139.

Foreign abstract

Černá D, Veselka J, Zimolová P, Blaško P, Fiedler J, Zemánek D, Duchoňová R, Malý M, Hájek P. Carotid artery stenting improves parameters of cerebrovascular hemodynamics. Am J Cardiol 2008; 101 (Suppl): 88C.

Černá D, Veselka J, Zimolová P, Blaško P, Fiedler J, Zemánek D, Duchoňová R, Malý M, Hájek P. Carotid artery stenting improves parameters of cerebrovascular hemodynamics. Circulation 2008; 118: E290.

Duchoňová R, Adla T, Veselka J, Neuwirth J, Martinkovičová L, Suchánek, V, Hájek, P, Malý M, Zemánek D. Radiation dose of dual-source ct is much higher compared to invasive coronary angiography. Circulation 2008; 117 (Suppl): 130.

Duchoňová R, Linhartová K, Martinkovičová L, Adla T, Neuwirth J, Veselka J. Comparison of left ventricular ejection fraction evaluated by dual source ct and two-dimensional echocardiography. Circulation 2008; 117 (Suppl): 154.

Fiedler J, Honek T, Linhartova K et al. Professional Divers with History of Decompression Sickness Have Much More Higher Prevalence of Right to Left Shunt Than in Those without Such Event and Reaveal Favorable Outcome during Mid-term Follow-up after the Transcatheter Closure. Circ 2008; 118: e321.

Hájek P, Macek M, Hladikova M, Malý M, Ošťádal P, Hansvenclova E et al. Pregnancy-associated plasma protein-A and proform of eosinophilic major basic protein in the detection of acute coronary syndrome. Atherosclerosis Abstr Suppl 2008; 9: 178.

Sterbakova G, Racek J, Topolcan O, Cerbak R, Linhartova K. Increased serum VCAM-1 level is independently associated with calcific aortic stenosis in coronary artery disease patients: a marker of neoangiogenesis activity? Eur Heart J 2008; 29: 648-649.

Linhartova K, Veselka J, Sterbakova G, et al. Lower serum Fetuin-A levels are associated with aortic sclerosis in patients with coronary artery disease and preserved renal function. Circulation 2008; 118: E354-E355.

Linhartova K, Sterbakova G, Bernat I, Kopalova I, Stetka F, Cerbak R. Higher left ventricular mass index predicts angina one year after valve surgery in calcific aortic stenosis with coronary artery disease Eur J Echocardiogr. 2008; 9: S230.

Veselka J, Zemánek D, Tomašov P, Duchoňová R, Linhartová K. Alcohol septal ablation for obstructive hypertrophic cardimyopathy: Ultra-low dose of alcohol is safe and effective. Am J Cardiol 2008; 101 (Suppl): 43C.

Veselka J, Černá D, Zimolová P, Šramko M, Tomek A, Šrámek M. Direct carotid stenting is feasible, safe and effective. Am J Cardiol 2008; 101 (Suppl): 16C.

Veselka J, Černá D, Zimolová P, Šramko M, Tomek A, Šrámek M. Direct carotid stenting in high-risk patients is effective. CEJV 2008; 7: 13-14.

Veselka J, Zemánek D, Tomašov P, Duchoňová R, Linhartová K. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: ultra-low dose of alcohol (1 ml) is still effective. Circulation 2008; 117 (Suppl): 3.

Veselka J, Černá D, Zimolová P, Šramko M, Tomek A, Šrámek M. Thirty-day outcome of carotid artery stenting using the FilterWire Protection System in high-risk patients. 50th Golden Anniversary Congress, Tokyo, Japan, Abstract book, p. 17.

Veselka J, Černá D, Zimolová P, et al. Early outcomes of direct carotid artery stenting without predilation in high-risk patients: Analysis of a single center registry. Circulation 2008; 118: E175.

Czech articles

Black D, Veselka J, Vaněk I. Left ventricular pseudonaneurysm as a complication of myocardial infarction. Cor Vasa 2007; 49: 369-72.

Černá D, Veselka J, Vaněk I., Linhartová K, Duchoňová R, Adla T, Horn M, Laca B. Left ventricular pseudonaneurysm as a complication of myocardial infarction. Cor Vasa 2007; 49: 369-72.

Černá D. Ultrasound examination of carotid arteries. Cardioforum 2007; 5: 5-11.

Foramen ovale patens as a cause of paradoxical embolization in divers. Screening options, therapeutic and preventive recommendations. Prakt Lék 2007; 87: 48-51.

Honěk T, Veselka J, Tomek A, Šrámek M, Januška J, Šefc L, Kerekeš R, Novotný Š. Paradoxical embolization in foramen ovale patens in divers: possibilities of screening.

Čerbák R, Linhartová K. News in the treatment of aortic stenosis. Internal Med 2007; 2: 88-90.

Linhartová K, Filipovský J, Čerbák R, Štěrbáková G. Drug treatment of arterial hypertension in patients with significant aortic stenosis. Cor Vasa 2007; 49: 192-4.

Ferda J, Linhartová K. Dobutamine-atropine stress test of myocardium using magnetic resonance imaging. Ces Radiol 2007; 61: 85-90.

Linhartová K. Drug treatment of hypertension - cardioprotective effect of ACE inhibitors. Causa subita 2007; 10: 111-112.

Linhartová K. How to treat patients with aortic stenosis? Cor Vasa 2007; 49: 287-288.

Linhartová K. Drug treatment of arterial hypertension in patients with aortic valve calcification. Causa subita 2007; 10: 146-147.

Linhartová K. Medication treatment of aortic stenosis. Medical Letters 2007; 21: 21-22.

Vejvoda J, Veselka J, Pádr R, Ošťádal P, Alan D, Tesař D. Catheterization treatment of carotid artery injury using stent graft implantation. Cor Vasa 2007; 49: 105-7.

Veselka J, Černá D, Blaško P. Combined catheterization intervention on the trunk of the left coronary artery and the left internal carotid artery. Cor Vasa 2007; 49: 391.

Veselka J, Zemánek D. Some myths about hypetrophic cardiomyopathy. Cor Vasa2007; 49: 391.

Veselka J, Treatment of carotid artery atherosclerosis obliterans: a future giant standing on clay feet for now. KF 2007; 5: 4.

Veselka J, Tesar D. Stenting of carotid arteries. KF 2007; 5: 34-7.

Veselka J. A cardiologist is wanted. Mark: Knowledge of CT and MR of the heart required. Cor Vasa 2007; 49: 346-7.
Šetina M, Veselka J, Mokráček A, Vaněk I. Current possibilities of robotic surgery. Vnitř Lék 2007; 53: 986-9.

Šetina M, Veselka J, Mokráček A, Vaněk I. Current possibilities of robotic cardiac surgery. Vnitř Lék 2007; 53: 645-8.

Echocardiographic image of the closure of the atrial septal defect of the ostium secundum type by the Amplatz occluder. Cor Vasa 2007; 49: 87.

Czech abstracts

Blaško P, Veselka J, Zemánek D, et al. Percutaneous coronary intervention of an unprotected ACS strain - 1-year follow-up. Cor Vasa 2007; 49: 8.

Blaško P, Fiedler, Černá D, Veselka J. Percutaneous valvoplasty of the aortic valve in critically ill patients. Cor Vasa 2007; 49: 8.

Black D, Veselka J, Duchoňová R. Carotid stenting in high - risk patients: 30 - day follow - up. Cor Vasa 2007; 49: 17.

Comparison of selected groups of patients with suspected clinically significant atrial septal integrity disorder and their medium - term results after catheter occlusion. Cor Vasa 2007; 49: 23.

Hájek P, Macek M, Hansvenclová E, Hladíková M, Houbová B, Malý M, Veselka J, Krebsová A. High level of PAPP-A is an indicator of a worse prognosis of patients with acute myocardial infarketm with ST elevation. Cor Vasa 2007; 49: 29.

Linhartová K, Štěrbáková G, Čerbák R, Racek J, Trefil L, Bernat I, Veselka J. Parathyroid hormone and calcified aortic stenosis. Cor Vasa 2007; 49: 61.

Veselka J, Non - pharmacological treatment of hypetrophic cardiomyopathy. Intervention 2007: 4-5.

Diastolic function of the left ventricle in hypertrophic cardiomyopathy - gradient effect in the outflow tract. Cor Vasa 2007; 49: 135.

Chapters in the monograph

Cerbak R et al. The most common valve defects: aortic stenosis and regurgitation: Linhartová K. Etiology, Echocardiographic diagnostics, Drug treatment of aortic stenosis. Galén 2007.

Foreign articles

Ostadal P, Alan D, Vejvoda J, Cepova J, Kukacka J, Blasko P, Martinkovicova L, Vojacek J. Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. Mol Cell Biochem 2007; 306: 19-23.

Durdil V, Fiedler J, Alan D, Vejvoda J, Veselka J. Multiple mobile aortic thrombosis treated by thrombolysis. J Thromb Thrombolysis 2007; 24: 315-6.

Linhartova K, Veselka J, Adla T. Left ventricular pseudoaneurysm as a late comp = lication of mitral annuloplasty. Eur Heart J 2007; 28: 2360.

Linhartova K, Beranek V, Šefrna F, Hanišová I, Sterbáková G, Pešková M. Aortic stenosis severity is not a ris factor of poststenotic dilatation of the ascending aorta.Cicr J 2007; 1: 84-88.

Linhartova K, Filipovsky J, Cerbak R, Sterbakova G, Hanisova I, Beranek V. Severe aortic stenosis and its association with hypertension: analysis of clinical and echocardiographic parameters. Blood Pressure 2007; 16: 122-28.

Linhartova K, Veselka J, Adla T. Left ventricular pseudoaneurysm as a late complication of mitral annuloplasty. Eur Heart J 2007; 19: 2360.

Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A rewiew of the literature. Med Sci Monit 2007; 13: RA62-8.

Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: focus on safety. Swiss Med Wkly 2007; 137: 657-9.

Veselka J, Černá D, Zimolová P, Blaško P, Fiedler J, Hajek P, Maly M, Zemanek D, Duchonova R. Thirty-day outcomes of direct carotid artery stenting with cerebralprotection in high-ris patients. Circ J 2007; 71: 1468-72.

Červinka P, Jabkačin J, Jager J, Veselka J, Kala P, Maly J. Long-term health outcome and mortality evaluation after invasive coronary treatment using drug-eluting stents: HOME DES registry. Coron Artery Dis 2007; 18: 577-81.

Zemanek D, Veselka J. Coronary anomalies - a short review. CEJMed 2007; 2: 140-153.

Foreign abstract

Hajek P, Macek Sr. M, Hansveclova E, Hladikova M, Houbova B, Maly M, Veselka J, Krebsova A. Higher admission levels of PAPP-A / pro MBP complex are associated with worse prognosis after STEMI. Eur Heart J 2007; 28: 566-7.

Spatenka J, Hucin B, Kobylka P, Honek T, Povysilova V, Burkert J, Tlaskal T, Gebauer R sen, Mokracek A. 25 years of allograft heart valve banking in the Czech Republic. 16th International Congress of the European Association of Tissue Banks, Abstract No. A-0076, p. 81 Budapest, Hungary, 17 - 20 October 10.

Adla T, Neuwirth J, Linhartova K, Duchonova R, Burkert J. Left ventricular pseudoaneurysm as a late complication of mitral annuloplasty: Value of dual sorce computed tomography. Book of abstracts ESCR 2007. Eur Radiol 2007; 10: 2725.

Linhartova K, Čerbák R, Štěrbáková G, Racek J, Trefil V, Topolčan O, Veselka J. Calcific aortic stenosis is independently associated with increased parathormone serum level in coronary artery disease patients. J Am Coll Cardiol 2007; 49: 310.

Linhartova K, Veselka J, Štěrbáková G, Racek J, Topolčan O, Cerbak R. Calcific aortic stenosis is independently associated with increased parathyroid hormone and Decreased Vitamin D levels in coronary artery disease Patients. Circulation 2007; 116: 679.

Maly M, Hrachovinova I, Tomasov P, Hajek P, BlaskoP, Salaj P, Veselka J. Tissue factor activity and the count of microparticles in the patiens with acute coronary syndromes. Eur Heart J 2007; 28: 668.

Veselka J, Zemanek D, Palenickova J, et al. Impact of ethanol dosing on long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a single-center, prospective, and randomized study. J Heart Dis 2007; 5: 104.

Zemanek D, Veselka J, Tomasov P, Sedlakova M, Linhartova K. Evaluation of the right ventricular function by strain in hypertrophic cardiomyopathy after septal ablation. J Heart Dis 2007; 5:55.

Zemanek D, Veselka J, Tomasov P, Fiserova M, Linhartova K. Right ventricular systolic function is not worse in patients with hypertrophic cardiomyopathy after successful septal ablation than in healthy subject: a strain study. Eur J Echocardiogr 2007; 8: 56.

Our department regularly organizes the PragueIntervention symposium focused on the latest diagnostic and treatment procedures in interventional cardiology, non-invasive cardiology and arrhythmology. Last year, the fifth year of this educational event took place in the Břevnov Monastery with the active participation of several foreign guests.

We are working on adding videos. Thank you for your understanding.

HOT Cardio 3

HOT Cardio 1/2

HOT Cardio 2/2

Pulmonary embolism

Cardiomyopathy

Valve defects

Atrial fibrillation

Coronary heart disease and its manifestations, Ischemic heart disease

Percutaneous aortic valve implantation, Percutaneous coronary intervention, Surgical endarterectomy

Percutaneous coronary intervention of the left coronary artery

Left ventricular electrode implantation

Catheter closure of multiple atrial septal defect

Catheter closure of atrial septal defect

Catheter ablation of AV nodal reentry tachycardia (AVNRT)

Non-selective catheter ablation of the AV junction

Catheterization of pulmonary veins with cryobalon

ICD implantation step by step

Carotid stenting

Catheter ablation of ventricular ectopy

Biventricular pacemaker implantation step by step

Catheter implantation of aortic bioprosthesis in a high-risk patient with LV systolic dysfunction

Alcohol septal ablation

Catheter treatment of femoral artery occlusion

Catheter implantation of an aortic bioprosthesis in an 86-year-old female patient

Electrical cardioversion

Covid - 19 Pneumonia - Care of hospitalized patients

www.infarktmyokardu.info

Head:

prof. MD Oštádal Petr, Ph.D., FESC
phone: 224 434 901, petr.ostadal@fnmotol.cz

Primary: 

MD Vejvoda Jiří, MHA phone: 224 434 952, jiri.vejvoda@fnmotol.cz

Head nurse:

M.Sc. Jana Kovalčíková, phone: 224 434 905, jana.kovalcikova@fnmotol.cz  

Secretariat:

Tasiula Irini
phone: 224 434 901
Email: irini.tasiula@fnmotol.cz

Reception

Pavlíčková Jana, Skoupa Marcela
tel .: 224 434 914, 224 434 967
mobile: 720 816 796
Green line: 800 333 356 (free calls)

Pavlíčková Jana
tel .: 224434914, 224434967
Email: jana.pavlickova2@fnmotol.cz
kardiologie@fnmotol.cz 

Patients for acute catheterization:

Catheterization room - phone: 224434961 during working hours
                                 tel.: 224434930 during non-working hours (doctor of the Coronary Unit)